NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.24 +0.11 (+0.99 %)
(As of 04/19/2019 04:00 PM ET)
Previous Close$11.13
Today's Range$10.92 - $11.31
52-Week Range$9.07 - $21.20
Volume904,667 shs
Average Volume1.48 million shs
Market Capitalization$1.74 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.91
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and Nicox SA to generate various therapeutics for the treatment of certain ophthalmic conditions, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IRWD
CUSIP46333X10
Phone617-621-7722

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$346.64 million
Book Value($1.27) per share

Profitability

Net Income$-282,370,000.00

Miscellaneous

EmployeesN/A
Market Cap$1.74 billion
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable

Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings data on Wednesday, February, 13th. The biotechnology company reported ($0.02) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.15. The biotechnology company earned $130.70 million during the quarter, compared to analyst estimates of $96.57 million. Ironwood Pharmaceuticals's revenue for the quarter was up 38.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.14) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Ironwood Pharmaceuticals.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals issued an update on its FY 2019 earnings guidance on Wednesday, February, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $377.33 million.

What price target have analysts set for IRWD?

12 equities research analysts have issued 12-month target prices for Ironwood Pharmaceuticals' shares. Their forecasts range from $13.00 to $25.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $17.35 in the next year. This suggests a possible upside of 54.4% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

What is the consensus analysts' recommendation for Ironwood Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

Has Ironwood Pharmaceuticals been receiving favorable news coverage?

News stories about IRWD stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ironwood Pharmaceuticals earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Ironwood Pharmaceuticals' key competitors?

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Micron Technology (MU), YY (YY), Allergan (AGN) and Aegean Marine Petroleum Network (ANW).

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the folowing people:
  • Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 55)
  • Ms. Gina R. Consylman CPA, CFO, Sr. VP & Treasurer (Age 46)
  • Dr. Mark G. Currie, Sr. VP, Chief Scientific Officer and Pres of R&D (Age 64)
  • Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 49)
  • Mr. Thomas A. McCourt, Pres (Age 62)

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Tibra Equities Europe Ltd (0.04%) and First Manhattan Co. (0.03%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

Which major investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was acquired by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd and First Manhattan Co.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $11.24.

How big of a company is Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals has a market capitalization of $1.74 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

What is Ironwood Pharmaceuticals' official website?

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]


MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  412 (Vote Outperform)
Underperform Votes:  501 (Vote Underperform)
Total Votes:  913
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel